SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

NVCN RSS Feed
Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: CoinOp, steez, l2 hunter
Search This Board:
Last Post: 9/26/2016 8:42:20 AM - Followers: 51 - Board type: Free - Posts Today: 1
                                                             
                                                                                                                                       
                                                                               
                       

                                                                                                       


                                                                                   Nasdaq: NVCN

                                                                                   
                                                                                      Contact Info
                                                                              
                                                                          
13562 Maycrest Way #5138, Richmond,

                                                                                  BC V6V 2j7 Canada
                                                                            Phone:1.604.270.4344
                                                                            Fax: 1.604.270.4384
                                                                            Email: info@neovasc.com
                                                                            Website: www.neovasc.com
                                                                 
          
                                                                                          


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 


 

Neovasc Tiara

Tiara is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.

Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.

The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.

Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.
http://www.neovasc.com/products/neovasc-tiara/

                                                                                                                                                                                                
 

Neovasc Reducer

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.
http://www.neovasc.com/products/neovasc-reducer/

                                                                                                             

__________________________________________________________________________________________________________________________________________________________                                                              

Opko Investee Neovasc $9B Massive and Virtually Unpenetrated Market Opportunity

                                   ****   Leerink Partners Starts Neovasc (NVCN) at Outperform, $15 PT ****


http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Starts+Neovasc+(NVCN)+at+Outperform,+$15+PT/10390409.html

https://opkodd.wordpress.com/2015/03/20/opko-investee-neovasc-9b-massive-and-virtually-unpenetrated-market-opportunity/
       
__________________________________________________________________________________________________________________________________________________________

                                          Successfully increasing financing year to year through Institutional Public Offerings
                              sets a tone to a growing Value in its Marketplace.


                                                               6-k dated May 2014 

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=10008601&RcvdDate=5/22/2014&CoName=NEOVASC%20INC&FormType=6-K&View=html 

"For the three months ended March 31, 2014, net cash provided by financing activities was $24,658,642 compared to $194,010 for the same period in 2013. On March 26, 2014, the Company closed a bought deal equity financing underwritten by Cormark Securities Inc., which placed 4,192,000 common shares of Neovasc at a price of $6.00 per common share, for gross cash proceeds to the Company of $25,152,000. The share issue cost was $506,651." 

                                                                6-k dated May 2015 

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=10691281&RcvdDate=5/12/2015&CoName=NEOVASC%20INC&FormType=6-K&View=html 


"For the three months ended March 31, 2015, net cash provided by financing activities was $88,143,429, compared to $24,658,642 for the same period in 2014. On February 3, 2015, the Company closed an underwritten public offering of 12,075,000 common shares of the Company (of which 10,415,000 common shares were issued from treasury and 1,660,000 common shares were sold by certain directors, officers and employees of the Company) at a price per share of US$7.19 for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the selling security holders. The share issue costs incurred by the Company were $6,236,783. "
_______________________________________________________________________________________________________________________________________________________________________________________________________________________


**NEWEST UPDATED INFO  6/15/16 - 6-K FILING SHOWS 81.28% Longs/Institutional Ownership from voting results**
 
NEOVASC INC.
(the “Company”)
 
Annual General Meeting of Shareholders
June 15, 2016
 
 
REPORT OF VOTING RESULTS
(Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations )
 
Common Shares represented at the Meeting:
 
54,540,817**
Total issued and outstanding Common Shares as at Record Date:
 
66,855,345
Percentage of issued and outstanding Common Shares represented:
 
81.58%
________________________________________________________________________________________________________________________________________________________

 http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11447721&RcvdDate=6/16/2016&CoName=NEOVASC%20INC&FormType=6-K&View=html
 

___________________________________________________________________________________________________________________________________________

 May 4 ,2016 6-k filing here has  #1 holder with 22.1% " Dr. Phillip Frost" of Frost Gamma Investments Trust  
 
Shareholder Name   Number of Shares Held     Percentage of Issued Shares  
             
Frost Gamma Investments Trust      14,786,219       22.1 %

  
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11400812&RcvdDate=5/20/2016&CoName=NEOVASC%20INC&FormType=6-K&View=html

_______________________________________________________________________________________________________________________________________________________________________________________________________________________

******Major Ownership Here: Funds & Institutions & Direct

Holders @Barrons has over

50+ Million Shares Owned !!! *****


****{ Major amount of this was purchased at the $6.00 & $7.00 level!! }



http://www.barrons.com/quote/stock/us/xnas/nvcn

_______________________________________________________________________________________________________________________________________________________________________________________________________________________
Outstanding Share Data 
August 9, 2016, the Company had 66,866,345 common voting shares issued and outstanding
 
"Remaining Non Dilutive to Shareholders as Direct Funding has been their proven successful funding arena"


August 6, 2015, the Company had 66,551,447 common shares issued and outstanding
August 12, 2014, the Company had 53,756,932 common voting shares issued and outstanding

_______________________________________________________________________________________________________________________________________________________________________________________________________________________
 

Most recent broker ratings
 

05/20/2016 – Neovasc Inc. was downgraded to “neutral” by analysts at Ladenburg Thalmann.

03/30/2016 – Neovasc Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 9.5 price target on the stock.

10/07/2015 – JMP Securities began new coverage on Neovasc Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock.

09/23/2015 – Neovasc Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

03/31/2015 – Northland Securities began new coverage on Neovasc Inc. giving the company a “outperform” rating. They now have a USD 12 price target on the stock.

___________________________________________________________________________________________________________________________________________________________________________________________________________________


                                                             





  Neovasc the small cap medical device company has a promising set of catalysts approaching for its core tissue division and for its two life saving vascular devices, The Reducer and The Tiara. The Reducer recently released extremely positive top line results of its sham-controlled COSIRA trial, and full results should be released by the end of the month. The device is already CE marked in Europe, and is the first minimally invasive treatment for Refractory Angina. Based off of comparable devices, the device can be worth anywhere from $5.00 to $14.00 per share.

The Tiara has received an extremely broad patent for treating Mitral Regurgitation, and is the frontrunner in bringing an effective product to the market for the first time ever. Neovasc tested the device in animals and recently published strong data supporting the safety and efficacy of the device. The first human implantation is scheduled for Q1 of 2014. If approved and brought to market, this would be a billion dollar device.

Neovasc's Peripatch tissue division continues to boast strong growth and profit numbers, as shown in its latest quarterly filing. This profitable division should see increased revenues as more of Neovasc's customers gain FDA approval for their vascular devices that utilize Neovasc's Peripatch tissue. The profit generated from the tissue division funds the development of The Reducer and The Tiara, which is unique for a small medical company, which would usually have to rely on secondary offerings (dilution) to generate the necessary development funds. The expanding growth of Neovasc and its tissue division will not end anytime soon as they finalize the divestment of its low margin patch division and benefit from the rapidly growing heart valve market.

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NVCN News: Report of Foreign Issuer (6-k) 08/09/2016 04:07:28 PM
NVCN News: Neovasc Reports Second Quarter Results for 2016 08/09/2016 04:00:00 PM
NVCN News: Neovasc Reports Second Quarter Results for 2016 08/09/2016 04:00:00 PM
NVCN News: August 5th Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of Deadline in the Class Action Lawsuit Against N... 08/04/2016 10:30:00 AM
NVCN News: DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Neovasc Inc. and a Lead Plai... 08/04/2016 10:12:16 AM
PostSubject
#392  Sticky Note Billionaire investor Philip Frost "Frost Gamma Investments Trust" CoinOp 06/11/16 09:53:55 PM
#1766   GM NVCN l2 hunter 09/26/16 08:42:20 AM
#1765   Lots of news will come out once they CoinOp 09/25/16 11:41:43 PM
#1764   Agreed... been here about 3 months so far cmoney1 09/25/16 02:07:12 PM
#1763   Its possible. I have earn about 2 million l2 hunter 09/25/16 01:44:18 PM
#1762   L2 Hunter... I would love to see $5 ish... cmoney1 09/25/16 12:45:12 PM
#1761   See many more like $ for NVCN. $2 l2 hunter 09/25/16 11:28:37 AM
#1760   700% and you are my hero but I knrorrel 09/25/16 07:49:28 AM
#1759   Watch for 400% * 700% bounce scenario l2 hunter 09/24/16 12:05:24 PM
#1758   In addition to all of that, some institution ttmasher 09/24/16 09:14:21 AM
#1757   going NVCN to 060-0,70 buy i and knrorrel 09/24/16 06:17:15 AM
#1756   NVCN 0.57$ Chart looking better and better. timebomb l2 hunter 09/23/16 03:52:58 PM
#1755   Yes back in June on the $1.28 run CoinOp 09/23/16 03:41:16 PM
#1754   0.57$ MA/50 break.... NVCN closely before massive bounce l2 hunter 09/23/16 01:38:40 PM
#1753   NVCN needs 60/70th at .56/.57 to break out? ttmasher 09/23/16 12:43:40 PM
#1752   I do agree, major holders want NVCN back ttmasher 09/23/16 12:36:31 PM
#1751   Thanks for the insight! And it seems that ttmasher 09/23/16 12:30:54 PM
#1750   Mutual funds own 11,294,000,Institutions own 17,000,000, Direct Holders CoinOp 09/23/16 12:23:30 PM
#1749   Your institutional holding number is wrong. FMR has llewxam 09/23/16 10:51:19 AM
#1748   NVCN setting for 500% 700% bounce... looking forward. l2 hunter 09/23/16 10:04:47 AM
#1747   Looking Good jb55 09/23/16 09:41:27 AM
#1746   Hold 100k NVCN shares for multi $ bounce l2 hunter 09/23/16 02:39:25 AM
#1745   Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September CoinOp 09/23/16 01:43:58 AM
#1744   Squeeze potential , another plus as NVCN is CoinOp 09/23/16 12:37:40 AM
#1743   Last Signal: BUY CoinOp 09/23/16 12:35:41 AM
#1742   NVCN heading up. Awesome!!! l2 hunter 09/22/16 10:57:48 AM
#1741   6 MONTH CHART >>>> l2 hunter 09/21/16 03:22:57 PM
#1740   Ma/50 breakout ahead l2 hunter 09/20/16 12:59:50 PM
#1739   Getting some buying now. jb55 09/20/16 12:46:30 PM
#1738   56 steez 09/20/16 12:45:23 PM
#1737   NVCN turning 55 now tic toc steez 09/20/16 12:42:07 PM
#1736   NVCN shift up under radar! $3 $4 bounce l2 hunter 09/20/16 12:16:51 PM
#1735   NVCN news should be basic and to the CoinOp 09/20/16 02:32:07 AM
#1733   GM NVCN l2 hunter 09/19/16 08:18:10 AM
#1732   It all sounds so good! But reality is, ttmasher 09/19/16 08:03:20 AM
#1731   Any expectations on 3rd Q financials? jb55 09/17/16 09:25:28 AM
#1730   4 Months coming up on this Mon/Tues since CoinOp 09/16/16 11:56:10 PM
#1729   EBIO has too much going IN The Mouth Of Madness 09/16/16 10:32:24 PM
#1728   There is a market maker "Y" that keeps jb55 09/16/16 11:07:49 AM
#1727   agree, NVCN my next EBIO bouncer imho... have l2 hunter 09/15/16 03:17:32 PM
#1726   nice L2 chart is the steez 09/15/16 01:17:24 PM
#1725   1% 2% Red is nothing for this stock. l2 hunter 09/15/16 12:23:00 PM
#1724   Long term uptrend will be tested here in SteezePleeze 09/15/16 12:01:59 PM
#1723   6. DAY resulted " R E D " knrorrel 09/15/16 09:58:39 AM
#1722   Right you are! Green days are not in ttmasher 09/15/16 09:44:39 AM
#1721   6 MONTH CHART >>>>>>>> l2 hunter 09/15/16 06:02:37 AM
#1720   Almost there, NVCN is ripe and at the CoinOp 09/15/16 12:45:19 AM
#1719   since 5 days, there are only "red" knrorrel 09/15/16 12:06:22 AM
#1718   can go fast. just watch my EBIO BCRX l2 hunter 09/14/16 02:25:26 PM
#1716   $2/4, is a long way off! NVCN needs ttmasher 09/14/16 10:14:51 AM
#1715   NVCN for me $2 $4 turn ahead. Save l2 hunter 09/14/16 09:15:00 AM
PostSubject